Business Description
Anatara Lifesciences Ltd
ISIN : AU000000ANR0
Description
Anatara Lifesciences Ltd develops and commercializes evidence-based products addressing unmet needs in gastrointestinal health. The company focuses on building a pipeline of human health products, particularly targeting complex gastrointestinal conditions. It operates through a single reportable segment encompassing the research and development of oral solutions for gastrointestinal diseases and the commercialization of Detach, a diarrhea treatment for piglets.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.67 | |||||
Equity-to-Asset | 0.85 | |||||
Debt-to-Equity | 0.36 | |||||
Debt-to-EBITDA | -0.53 | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 32.1 | |||||
3-Year EPS without NRI Growth Rate | 32.1 | |||||
3-Year FCF Growth Rate | 27.6 | |||||
3-Year Book Growth Rate | -43.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 43.67 | |||||
9-Day RSI | 50.88 | |||||
14-Day RSI | 52.89 | |||||
3-1 Month Momentum % | 11.11 | |||||
6-1 Month Momentum % | -28.57 | |||||
12-1 Month Momentum % | 66.67 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 7.02 | |||||
Quick Ratio | 7.02 | |||||
Cash Ratio | 5.74 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -39.6 | |||||
Shareholder Yield % | -34.21 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -129.9 | |||||
ROA % | -92.75 | |||||
ROIC % | -471.53 | |||||
3-Year ROIIC % | 16.84 | |||||
ROC (Joel Greenblatt) % | -495.18 | |||||
ROCE % | -76.01 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 2.5 | |||||
EV-to-EBIT | -4.5 | |||||
EV-to-EBITDA | -4.5 | |||||
EV-to-FCF | -3.18 | |||||
Earnings Yield (Greenblatt) % | -22.22 | |||||
FCF Yield % | -34.49 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Anatara Lifesciences Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | |||
| EPS (TTM) (A$) | -0.006 | ||
| Beta | 2.3593 | ||
| 3-Year Sharpe Ratio | 0.22 | ||
| 3-Year Sortino Ratio | 0.34 | ||
| Volatility % | 98.7 | ||
| 14-Day RSI | 52.89 | ||
| 14-Day ATR (A$) | 0.000286 | ||
| 20-Day SMA (A$) | 0.00995 | ||
| 12-1 Month Momentum % | 66.67 | ||
| 52-Week Range (A$) | 0.0055 - 0.02 | ||
| Shares Outstanding (Mil) | 315.95 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Anatara Lifesciences Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Anatara Lifesciences Ltd Stock Events
| Event | Date | Price (A$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Anatara Lifesciences Ltd Frequently Asked Questions
What is Anatara Lifesciences Ltd(ASX:ANR)'s stock price today?
The current price of ASX:ANR is A$0.01. The 52 week high of ASX:ANR is A$0.02 and 52 week low is A$0.01.
When is next earnings date of Anatara Lifesciences Ltd(ASX:ANR)?
The next earnings date of Anatara Lifesciences Ltd(ASX:ANR) is .
Does Anatara Lifesciences Ltd(ASX:ANR) pay dividends? If so, how much?
Anatara Lifesciences Ltd(ASX:ANR) does not pay dividend.
Press Release
| Subject | Date | ||
|---|---|---|---|
| ObvioHealth Partners with Anatara Lifesciences to Launch First-of-its-kind Decentralized Clinical Trial in Australia | 2021-09-30 |
Articles on Anatara Lifesciences Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers